miRNA-29b Inhibits Prostate Tumor Growth and Induces Apoptosis by Increasing Bim Expression

Cancer statistics, 2019

(2019) Rebecca L. Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Systematic Review of miR-29 in Cancer

(2019) Jason J. Kwon et al.   Molecular Therapy-Oncolytics

The role and mechanisms of action of microRNAs in cancer drug resistance

(2019) Wengong Si et al.   Clinical Epigenetics

The Potential for microRNA Therapeutics and Clinical Research

(2019) Johora Hanna et al.   Frontiers in Genetics

Noncoding RNA:RNA Regulatory Networks in Cancer

(2018) Jia Chan et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Expression of miR-30c and miR-29b in prostate cancer and its diagnostic significance

(2018) Chuanan Zhu et al.   Oncology Letters

Combined Effect of Anticancer Agents and Cytochrome C Decorated Hybrid Nanoparticles for Liver Cancer Therapy

(2018) Wejdan Al-Shakarchi et al.   Pharmaceutics

Potential regulatory roles of microRNAs and long noncoding RNAs in anticancer therapies

(2018) Mengyan Xie et al.   Molecular Therapy-Nucleic Acids

Akt2 mediates glucocorticoid resistance in lymphoid malignancies through FoxO3a/Bim axis and serves as a direct target for resistance reversal

(2018) Mixue Xie et al.   Cell Death & Disease

BH3-only protein BIM: An emerging target in chemotherapy

(2017) Shatrunajay Shukla et al.   EUROPEAN JOURNAL OF CELL BIOLOGY

Micrornas in prostate cancer: an overview

(2017) Daniela Vanacore et al.   Oncotarget

Meta-analysis of miRNA expression profiles for prostate cancer recurrence following radical prostatectomy

(2017) Elnaz Pashaei et al.   PLoS One

miRNA Deregulation in Cancer Cells and the Tumor Microenvironment

(2016) R. Rupaimoole et al.   Cancer Discovery

In vivo delivery of miRNAs for cancer therapy: Challenges and strategies

(2015) Yunching Chen et al.   ADVANCED DRUG DELIVERY REVIEWS

Bim directly antagonizes Bcl-xl in doxorubicin-induced prostate cancer cell apoptosis independently of p53

(2015) Min-Chi Yang et al.   CELL CYCLE

The role of miR-29b in cancer: regulation, function, and signaling

(2015) Jin-Rui Yang et al.   OncoTargets and Therapy

The Pro-Apoptotic BH3-Only Protein Bim Interacts with Components of the Translocase of the Outer Mitochondrial Membrane (TOM)

(2015) Daniel O. Frank et al.   PLoS One

DNA-demethylating and anti-tumor activity of synthetic miR-29b mimics in multiple myeloma

(2015) Nicola Amodio et al.   Oncotarget

Bitter Melon Reduces Head and Neck Squamous Cell Carcinoma Growth by Targeting c-Met Signaling

(2013) Ananthi Rajamoorthi et al.   PLoS One

Coordinated Silencing of MYC-Mediated miR-29 by HDAC3 and EZH2 as a Therapeutic Target of Histone Modification in Aggressive B-Cell Lymphomas

(2012) Xinwei Zhang et al.   CANCER CELL

Hepatic miR-29ab1 expression modulates chronic hepatic injury

(2012) Takayuki Kogure et al.   JOURNAL OF CELLULAR AND MOLECULAR MEDICINE

miRNA-29b Suppresses Prostate Cancer Metastasis by Regulating Epithelial-Mesenchymal Transition Signaling

(2012) P. Ru et al.   MOLECULAR CANCER THERAPEUTICS

Knockdown of autophagy enhances the innate immune response in hepatitis C virus-infected hepatocytes

(2010) Shubham Shrivastava et al.   HEPATOLOGY

Transcriptional suppression of mir-29b-1/mir-29a promoter by c-Myc, hedgehog, and NF-kappaB

(2010) Justin L. Mott et al.   JOURNAL OF CELLULAR BIOCHEMISTRY

MicroRNA 29b functions in acute myeloid leukemia

(2009) R. Garzon et al.   BLOOD

Induction of Tumor Cell Apoptosis or Necrosis by Conditional Expression of Cell Death Proteins: Analysis of Cell Death Pathways and In Vitro Immune Stimulatory Potential

(2009) C. Lohmann et al.   JOURNAL OF IMMUNOLOGY

Bim-targeted cancer therapy: A link between drug action and underlying molecular changes

(2009) T. Akiyama et al.   MOLECULAR CANCER THERAPEUTICS

MicroRNA profile analysis of human prostate cancers

(2008) A W Tong et al.   CANCER GENE THERAPY

The Inhibition of the Highly Expressed Mir-221 and Mir-222 Impairs the Growth of Prostate Carcinoma Xenografts in Mice

(2008) Neri Mercatelli et al.   PLoS One